| HOME >> BIOLOGY >> TECHNOLOGY |
Common Stock in Equity
NON-GAAP Equivalents Securities
Income Statement Classification:
Total revenues $1,171,134
Cost of products and services sold $(294,019)
Selling, general and administrative $(315,401)
Research and development $(190,769)
Amortization of intangibles $-
Purchase of in-process research
and development $-
Equity in income (loss) of equity
method investments $-
Minority interest $563
Gains (losses) on investments in
equity securities $138 $9,015
Other $19
Investment income $13,352
Interest expense $(1,149)
Summary:
Income (loss) before income taxes $383,868 $- $9,015
(Provision for) benefit from
income taxes $(115,322) $- $(3,283)
Net income (loss) $268,546 $- $5,732
Net income (loss) per share:
Basic $1.01 $- $0.02
Diluted (1) $0.98 $(0.03) $0.02
Weighted average shares outstanding:
Basic 266,904
Diluted (1) 274,576 9,686
License FAS 123R GAAP
Fee Amortization Expense As Reported
Income Statement
Classification:
Total revenues $1,171,134
Cost of products and<
'/>"/>
| SOURCE Genzyme Corporation Copyright©2008 PR Newswire. All rights reserved |